GlaxoSmithKline Plc has agreed to pay $23 million upfront for exclusive access to technology developed by Amplimmune Inc of the US for potential therapies for cancer and other diseases. Specifically, GSK will obtain rights to a molecule targeting the membrane protein, PD-1.
